川端 浩 かわばた ひろし 先生

来歴等

略歴

1988年 京都大学医学部 卒業
1988年 京都大学医学部附属病院 内科研修医
1989年 市立島田市民病院 内科研修医
1991年 京都大学大学院医学研究科博士課程（内科系専攻） 入学
1995年 京都大学医学部 研修員
1996年 シーダス・サイナイ・メディカルセンター 留学
2000年 金沢医科大学 血液免疫内科学 講師
2005年 京都大学医学研究科 血液・腫瘍内科 助手
2010年 京都大学医学研究科 血液・腫瘍内科 講師
2016年 金沢医科大学 血液免疫内科学 特任教授
2016年 金沢医科大学病院 血液センター 部長
2021年 京都医療センター 血液内科医長／診療科長（稀少血液疾患科）／ 臨床検査科副科長／輸血管理士

論文

• Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol. 2019, 110(5):533-542.

  Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A,Japanese National Research Group on Idiopathic Bone Marrow Failure S

• Transferrin and transferrin receptors update. Free Radic Biol Med. 2019, 13346-54.

  Kawabata H

• Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019, 94975-983.

  Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y

• The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol. 2018, 107(1):31-43.

  Kawabata H

• Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. Int J Hematol. 2017, 106(3):375–384.

  Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Zaike Y, Usuki K, Chiba S, Ishikawa T, Arima N, Nogawa M, Ohta A, Miyazaki Y, Mitani K, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A, Japanese National Research Group on Idiopathic Bone Marrow Failure S

• A Japanese family with X-linked sideroblastic anemia affecting females and manifesting as macrocytic anemia. Int J Hematol. 2016, 103(6):713-717.

  Katsurada T, Kawabata H, Kawabata D, Kawahara M, Nakabo Y, Takaori-Kondo A, Yoshida Y

• The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis. Cancer Med. 2015, 4(10):1558-1572.

  Uchiyama T, Kawabata H, Miura Y, Yoshioka S, Iwasa M, Yao H, Sakamoto S, Fujimoto M, Haga H, Kadowaki N, Maekawa T, Takaori-Kondo A

• H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner. PLoS One. 2015, 10(10):e0139915.

  Sakamoto S, Kawabata H, Masuda T, Uchiyama T, Mizumoto C, Ohmori K, Koeffler HP, Kadowaki N, Takaori-Kondo A

• A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015, 43(5):404-413 e405.

  Kawabata H, Uchiyama T, Sakamoto S, Kanda J, Oishi S, Fujii N, Tomosugi N, Kadowaki N, Takaori-Kondo A

• A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012). J Clin Exp Hematop. 2013, 53(1):57-61.

  Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y: Castleman-Kojima Disease (TAFRO Syndrome)

• Clinical Features and Treatment of Multicentric Castleman's Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop. 2013, 53(1):69-77.

  Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A

• A Case of Congenital Dyserythropoietic Anemia Type 1 in a Japanese Adult with a CDAN1 Gene Mutation and an Inappropriately Low Serum Hepcidin-25 Level. Intern Med. 2012, 51(8):917-920.

  Kawabata H, Doisaki S, Okamoto A, Uchiyama T, Sakamoto S, Hama A, Hosoda K, Fujikura J, Kanno H, Fujii H, Tomosugi N, Nakao K, Kojima S, Takaori-Kondo A

• Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica. 2007, 92(6):857-858.

  Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T

• Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006, 108(4):1381-1387.

  Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I

• Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005, 105(1):376-381.

  Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, Umehara Y, Wano Y, Said JW, Koeffler HP

• Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood. 2001, 98(9):2714-2719.

  Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germain RS, Koeffler HP

• Regulation of expression of murine transferrin receptor 2. Blood. 2001, 98(6):1949-1954.

  Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, Koeffler HP

• Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem. 2000, 275(22):16618-16625.

  Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP

• Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem. 1999, 274(30):20826-20832.

  Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, Koeffler HP

• 【MDSの治療：本邦における治療の現状】治療ガイドライン. 日本臨床. 2019, 77(9):1483-1488.

  川端浩

• キャッスルマン病の診断の進め方. 成人病と生活習慣病. 2018, 48(12):1319-1324.

  川端浩, 藤本信乃, 坂井知之, 岩男悠, 河南崇典, 藤田義正, 福島俊洋, 水田秀一, 正木康史

• MDSと鉄代謝. 臨床血液. 2018, 59(10):2042-2049.

  川端浩

• 鉄代謝研究の進歩. 臨床血液. 2017, 58(10):56-63.

  川端浩

• 赤血球造血におけるトランスフェリン受容体の役割. 臨床血液. 2016, 57(7):951-958.

  川端浩, 坂本宗一郎, 増田太郎, 内山達樹, 大森勝之, Koeffler HP, 高折晃史

• 鉄剤不応性の鉄欠乏性貧血. 臨床血液. 2016, 57(2):104-109.

  川端浩

• 赤血球の生理機能と産生調節. 日本内科学会雑誌. 2015, 104(7):1367-1374.

  川端 浩, 高折 晃

その他

• 【対応可能な言語】日本語

• 【対応可能な言語】英語